Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy
Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).
December 14, 2021
by prnasia
AZD7442 reduces COVID-19 risks by 83 percent in Phase III trial
AstraZeneca has announced new data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials which both showed robust efficacy from a one-time intramuscular...
November 26, 2021
by EuropeanPharmaceuticalReview
New Analyses of Two AZD7442 Covid-19 Trials Confirm Robust Efficacy and Long-Term Prevention in High-Risk Populations
New data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials both showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.
November 22, 2021
by AmericanPharmaceuticalReview
New analyses of two AZD7442 COVID-19 phase-III trials in high-risk populations confirm robust efficacy and long-term prevention
AstraZeneca yesterday said that new data from the AZD7442 COVID-19 Provent prevention and Tackle outpatient treatment phase-III trials showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.
November 19, 2021
by ExpressPharma
Update on AZD7442 STORM CHASER Trial in Post-Exposure Prevention of Symptomatic COVID-19
AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.
June 29, 2021
by drugs
STORM CHASER Trial Fails to Meet Primary Endpoint in Post-Exposure Prevention of Symptomatic COVID-19
AstraZeneca announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.
June 17, 2021
by americanpharmaceuticalreview
Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment
AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19.
March 22, 2021
by worldpharmanews
AstraZeneca to supply 500,000 additional doses of COVID-19 antibody cocktail to US
The drugmaker said the $205 million US extension for 500,000 antibody doses builds on a contract agreed with government agencies in October for initial supplies of 200,000 doses of the antibody cocktail, AZD7442.
March 22, 2021
by expresspharma
AstraZeneca to supply 500,000 doses of Covid-19 antibody to the US
AstraZeneca (AZ) has signed an agreement with the US Department of Health and Human Services (HHS) and the Department of Defense (DoD) for the supply of up to 500,000 additional doses of its Covid-19 antibody treatment for $205m.
March 18, 2021
by pharmaceutical-technology
Trial to assess AstraZeneca’s long-acting COVID-19 antibody therapy
The ACTIV-3 sub-study will evaluate the safety and efficacy of the AZD7442 synthetic antibody combination in at least 150 participants with mild-to-moderate COVID-19.
February 10, 2021
by europeanpharmaceuticalreview
Matrix Collaborates with AstraZeneca on Trial for COVID-19 Long-Acting Antibody Combination
Matrix Medical Network® announced a collaboration with AstraZeneca to accelerate a clinical trial in the US for AZD7442, AstraZeneca's long-acting monoclonal antibody (LAAB) combination for the potential prevention of COVID-19.
February 9, 2021
by americanpharmaceuticalreview
Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial
Care Access to provide decentralized, mobile research site operations for AstraZeneca’s AZD7442 Phase III trial in the U.S.
January 27, 2021
by contractpharma